{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T16:59:28Z","timestamp":1785517168255,"version":"3.56.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2023M741278"],"award-info":[{"award-number":["2023M741278"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Key R & D Program of Hubei Province","award":["2023BCB149"],"award-info":[{"award-number":["2023BCB149"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370770"],"award-info":[{"award-number":["82370770"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Bladder cancer remains a significant clinical challenge due to high recurrence and progression rates, necessitating novel therapeutic strategies. Oncolytic viruses, such as the herpes simplex virus type 2-based OHSV2, have demonstrated promising antitumor effects through direct oncolysis and immune activation. This study investigated the efficacy, safety, and molecular mechanisms of OHSV2 in the treatment of bladder cancer.\u00a0In vitro and in vivo experiments demonstrated that OHSV2 potently inhibited bladder cancer cell proliferation, migration, and clonogenicity in a dose-dependent manner, while exhibiting a favorable safety profile. Critically, OHSV2 treatment triggered a pro-inflammatory tumor immune microenvironment, characterized by increased infiltration and activation of CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells. Mechanistically, OHSV2 induced pyroptosis in bladder cancer cells via the canonical\u00a0Caspase-1\/Gasdermin D (GSDMD) pathway, accompanied by increased interleukin-18 (IL-18), interleukin-1\u03b2 (IL-1\u03b2), and lactate dehydrogenase (LDH) release. Further analysis identified\u00a0NOD-like receptor family pyrin domain containing 3 (NLRP3)\u00a0as the key upstream pattern recognition receptor for Caspase-1\/GSDMD activation, and\u00a0Toll-like receptor 4 (TLR4)\u00a0as a critical mediator of NLRP3-dependent pyroptosis. Inhibition of TLR4 or NLRP3 partially reversed OHSV2-induced cytotoxicity, confirming their functional roles. Additionally, combining OHSV2 with the TLR4 agonist\u00a0enhanced pyroptosis in a subcutaneous xenograft model, amplified antitumor immunity, and improved tumor control in vivo, suggesting potential synergism for clinical translation. These findings elucidate a novel\u00a0TLR4\/NLRP3\/Caspase-1\/GSDMD axis as the core mechanism behind the antitumor effect of OHSV2 and propose a rationale for its combination with immunomodulators to improve outcomes in bladder cancer.\n                  <\/jats:p>","DOI":"10.1186\/s43556-026-00506-4","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T10:13:49Z","timestamp":1785233629000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oncolytic virus OHSV2 induces pyroptosis in bladder cancer cells via the TLR4\/NLRP3\/Caspase-1\/GSDMD pathway"],"prefix":"10.1186","volume":"7","author":[{"given":"Jinzhou","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenqian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyu","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binlei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qidong","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3206-1495","authenticated-orcid":false,"given":"Shaogang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"issue":"3","key":"506_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"506_CR2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41585-024-00914-7","volume":"22","author":"M Olislagers","year":"2025","unstructured":"Olislagers M, de Jong FC, Rutten VC, Boormans JL, Mahmoudi T, Zuiverloon TCM. Molecular biomarkers of progression in non-muscle-invasive bladder cancer - beyond conventional risk stratification. Nat Rev Urol. 2025;22(2):75\u201391. https:\/\/doi.org\/10.1038\/s41585-024-00914-7.","journal-title":"Nat Rev Urol"},{"key":"506_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16193330","author":"F Guerrero-Ramos","year":"2024","unstructured":"Guerrero-Ramos F, Gonz\u00e1lez-Padilla DA, P\u00e9rez-Cadavid S, Garc\u00eda-Rojo E, Tejido-S\u00e1nchez \u00c1, Hern\u00e1ndez-Arroyo M, et al. Muscle-invasive bladder cancer in non-curative patients: a study on survival and palliative care needs. Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/cancers16193330.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"506_CR4","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/1097-0142(194905)2:3<525::aid-cncr2820020317>3.0.co;2-o","volume":"2","author":"AE Moore","year":"1949","unstructured":"Moore AE. The destructive effect of the virus of Russian Far East encephalitis on the transplantable mouse sarcoma 180. Cancer. 1949;2(3):525\u201334. https:\/\/doi.org\/10.1002\/1097-0142(194905)2:3%3c525::aid-cncr2820020317%3e3.0.co;2-o.","journal-title":"Cancer"},{"issue":"1","key":"506_CR5","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41392-022-00951-x","volume":"7","author":"Y Tian","year":"2022","unstructured":"Tian Y, Xie D, Yang L. Engineering strategies to enhance oncolytic viruses in cancer immunotherapy. Signal Transduct Target Ther. 2022;7(1):117. https:\/\/doi.org\/10.1038\/s41392-022-00951-x.","journal-title":"Signal Transduct Target Ther"},{"key":"506_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvr.2025.200333","volume":"20","author":"G Cao","year":"2025","unstructured":"Cao G, Ding C, Dai J, Qiu X. Oncolytic virus and immunogenic cell death in cancer therapy. Tumour Virus Res. 2025;20:200333. https:\/\/doi.org\/10.1016\/j.tvr.2025.200333.","journal-title":"Tumour Virus Res"},{"issue":"13","key":"506_CR7","doi-asserted-by":"publisher","first-page":"4166","DOI":"10.7150\/ijbs.86855","volume":"19","author":"H Huang","year":"2023","unstructured":"Huang H, Weng Y, Tian W, Lin X, Chen J, Luo L. Molecular mechanisms of pyroptosis and its role in anti-tumor immunity. Int J Biol Sci. 2023;19(13):4166\u201380. https:\/\/doi.org\/10.7150\/ijbs.86855.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"506_CR8","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41467-023-35917-2","volume":"14","author":"J Lin","year":"2023","unstructured":"Lin J, Sun S, Zhao K, Gao F, Wang R, Li Q, et al. Oncolytic Parapoxvirus induces Gasdermin E-mediated pyroptosis and activates antitumor immunity. Nat Commun. 2023;14(1):224. https:\/\/doi.org\/10.1038\/s41467-023-35917-2.","journal-title":"Nat Commun"},{"issue":"1","key":"506_CR9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.tim.2024.07.001","volume":"33","author":"E Gerber-Tichet","year":"2025","unstructured":"Gerber-Tichet E, Blanchet FP, Majzoub K, Kremer EJ. Toll-like receptor 4 - a multifunctional virus recognition receptor. Trends Microbiol. 2025;33(1):34\u201347. https:\/\/doi.org\/10.1016\/j.tim.2024.07.001.","journal-title":"Trends Microbiol"},{"key":"506_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2024.578401","volume":"393","author":"C Lei","year":"2024","unstructured":"Lei C, Chen K, Gu Y, Li Y, Wang L, Zhu X, et al. HMGB1\/TLR4 axis promotes pyroptosis after ICH by activating the NLRP3 inflammasome. J Neuroimmunol. 2024;393:578401. https:\/\/doi.org\/10.1016\/j.jneuroim.2024.578401.","journal-title":"J Neuroimmunol"},{"key":"506_CR11","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00212-24","author":"N Jian","year":"2025","unstructured":"Jian N, Yu L, Ma L, Zheng B, Huang W. BCG therapy in bladder cancer and its tumor microenvironment interactions. Clin Microbiol Rev. 2025. https:\/\/doi.org\/10.1128\/cmr.00212-24.","journal-title":"Clin Microbiol Rev"},{"key":"506_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11010086","author":"PRZ Antas","year":"2022","unstructured":"Antas PRZ, da Silva ASM, Albuquerque LHP, Almeida MR, Pereira E, Castello-Branco LRR, et al. The BCG Moreau vaccine upregulates in vitro the expression of TLR4, B7-1, Dectin-1 and EP2 on human monocytes. Vaccines (Basel). 2022. https:\/\/doi.org\/10.3390\/vaccines11010086.","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"506_CR13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/mt.2013.238","volume":"22","author":"ST Workenhe","year":"2014","unstructured":"Workenhe ST, Simmons G, Pol JG, Lichty BD, Halford WP, Mossman KL. Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy. Mol Ther. 2014;22(1):123\u201331. https:\/\/doi.org\/10.1038\/mt.2013.238.","journal-title":"Mol Ther"},{"issue":"30","key":"506_CR14","doi-asserted-by":"publisher","first-page":"21348","DOI":"10.18632\/oncotarget.25096","volume":"9","author":"X Fu","year":"2018","unstructured":"Fu X, Tao L, Wang PY, Cripe TP, Zhang X. Comparison of infectivity and spread between HSV-1 and HSV-2 based oncolytic viruses on tumor cells with different receptor expression profiles. Oncotarget. 2018;9(30):21348\u201358. https:\/\/doi.org\/10.18632\/oncotarget.25096.","journal-title":"Oncotarget"},{"key":"506_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010543","author":"Z Tan","year":"2025","unstructured":"Tan Z, Wu Y, Fan Z, Gao T, Ding S, Han L, et al. Intratumoral oncolytic virus OH2 injection in patients with locally advanced or metastatic sarcoma: a phase 1\/2 trial. J Immunother Cancer. 2025. https:\/\/doi.org\/10.1136\/jitc-2024-010543.","journal-title":"J Immunother Cancer"},{"issue":"17","key":"506_CR16","doi-asserted-by":"publisher","first-page":"7371","DOI":"10.7150\/thno.74075","volume":"12","author":"Q Wu","year":"2022","unstructured":"Wu Q, Hu X, Zhang X, Kong D, Yang Z, Li G, et al. Single-cell transcriptomics of peripheral blood reveals anti-tumor systemic immunity induced by oncolytic virotherapy. Theranostics. 2022;12(17):7371\u201389. https:\/\/doi.org\/10.7150\/thno.74075.","journal-title":"Theranostics"},{"issue":"1","key":"506_CR17","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1186\/s12916-022-02574-z","volume":"20","author":"D Kong","year":"2022","unstructured":"Kong D, Yang Z, Li G, Wu Q, Gu Z, Wan D, et al. SIRP\u03b1 antibody combined with oncolytic virus OH2 protects against tumours by activating innate immunity and reprogramming the tumour immune microenvironment. BMC Med. 2022;20(1):376. https:\/\/doi.org\/10.1186\/s12916-022-02574-z.","journal-title":"BMC Med"},{"issue":"3","key":"506_CR18","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/s0966-842x(00)01945-4","volume":"9","author":"CA D'Souza","year":"2001","unstructured":"D\u2019Souza CA, Heitman J. Dismantling the Cryptococcus coat. Trends Microbiol. 2001;9(3):112\u20133. https:\/\/doi.org\/10.1016\/s0966-842x(00)01945-4.","journal-title":"Trends Microbiol"},{"issue":"1","key":"506_CR19","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12967-024-04930-4","volume":"22","author":"CBL Victorio","year":"2024","unstructured":"Victorio CBL, Novera W, Ganasarajah A, Ong J, Thomas M, Wu J, et al. Repurposing of Zika virus live-attenuated vaccine (ZIKV-LAV) strains as oncolytic viruses targeting human glioblastoma multiforme cells. J Transl Med. 2024;22(1):126. https:\/\/doi.org\/10.1186\/s12967-024-04930-4.","journal-title":"J Transl Med"},{"issue":"1","key":"506_CR20","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41420-023-01466-2","volume":"9","author":"A Wu","year":"2023","unstructured":"Wu A, Li Z, Wang Y, Chen Y, Peng J, Zhu M, et al. Recombinant measles virus vaccine rMV-Hu191 exerts an oncolytic effect on esophageal squamous cell carcinoma via caspase-3\/GSDME-mediated pyroptosis. Cell Death Discov. 2023;9(1):171. https:\/\/doi.org\/10.1038\/s41420-023-01466-2.","journal-title":"Cell Death Discov"},{"issue":"2","key":"506_CR21","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02097-21","volume":"10","author":"SM Choudhury","year":"2022","unstructured":"Choudhury SM, Ma X, Zeng Z, Luo Z, Li Y, Nian X, et al. Senecavirus a 3D interacts with NLRP3 to induce IL-1\u03b2 production by activating NF-\u03baB and ion channel signals. Microbiol Spectr. 2022;10(2):e0209721. https:\/\/doi.org\/10.1128\/spectrum.02097-21.","journal-title":"Microbiol Spectr"},{"key":"506_CR22","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.virol.2016.05.023","volume":"496","author":"B Wang","year":"2016","unstructured":"Wang B, Zhu J, Li D, Wang Y, Zhan Y, Tan L, et al. Newcastle disease virus infection induces activation of the NLRP3 inflammasome. Virology. 2016;496:90\u20136. https:\/\/doi.org\/10.1016\/j.virol.2016.05.023.","journal-title":"Virology"},{"issue":"2","key":"506_CR23","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.virol.2006.12.032","volume":"362","author":"P Georgel","year":"2007","unstructured":"Georgel P, Jiang Z, Kunz S, Janssen E, Mols J, Hoebe K, et al. Vesicular stomatitis virus glycoprotein G activates a specific antiviral Toll-like receptor 4-dependent pathway. Virology. 2007;362(2):304\u201313. https:\/\/doi.org\/10.1016\/j.virol.2006.12.032.","journal-title":"Virology"},{"issue":"9","key":"506_CR24","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nrurol.2013.153","volume":"10","author":"H LaRue","year":"2013","unstructured":"LaRue H, Ayari C, Bergeron A, Fradet Y. Toll-like receptors in urothelial cells\u2013targets for cancer immunotherapy. Nat Rev Urol. 2013;10(9):537\u201345. https:\/\/doi.org\/10.1038\/nrurol.2013.153.","journal-title":"Nat Rev Urol"},{"issue":"2","key":"506_CR25","doi-asserted-by":"publisher","first-page":"142","DOI":"10.32471\/exp-oncology.2312-8852.vol-43-no-2.16102","volume":"43","author":"PG Yakovlev","year":"2021","unstructured":"Yakovlev PG, Gorbach OI, Ostapchenko LI, Garmanchuk LV, Skachkova OV, Khranovska NM, et al. Expression of TLR4 and major inflammatory cytokines in patients with bladder cancer of different grade and stage. Exp Oncol. 2021;43(2):142\u20138. https:\/\/doi.org\/10.32471\/exp-oncology.2312-8852.vol-43-no-2.16102.","journal-title":"Exp Oncol"},{"key":"506_CR26","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.carbpol.2014.11.012","volume":"118","author":"GW Zhang","year":"2015","unstructured":"Zhang GW, Qin GF, Han B, Li CX, Yang HG, Nie PH, et al. Efficacy of Zhuling polyporus polysaccharide with BCG to inhibit bladder carcinoma. Carbohydr Polym. 2015;118:30\u20135. https:\/\/doi.org\/10.1016\/j.carbpol.2014.11.012.","journal-title":"Carbohydr Polym"},{"issue":"3","key":"506_CR27","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.7314\/apjcp.2014.15.3.1321","volume":"15","author":"YH Wang","year":"2014","unstructured":"Wang YH, Cao YW, Yang XC, Niu HT, Sun LJ, Wang XS, et al. Effect of TLR4 and B7\u2013H1 on immune escape of urothelial bladder cancer and its clinical significance. Asian Pac J Cancer Prev. 2014;15(3):1321\u20136. https:\/\/doi.org\/10.7314\/apjcp.2014.15.3.1321.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"1","key":"506_CR28","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1186\/s12917-024-04411-2","volume":"20","author":"HL Dong","year":"2024","unstructured":"Dong HL, Wu XY, Wang FY, Chen HX, Feng SL, Zhou CY, et al. Mechanism of activation of TLR4\/NF-\u03baB\/NLRP3 signaling pathway induced by heat stress disrupting the filtration barrier in broiler. BMC Vet Res. 2024;20(1):584. https:\/\/doi.org\/10.1186\/s12917-024-04411-2.","journal-title":"BMC Vet Res"},{"issue":"4","key":"506_CR29","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1189\/jlb.0603280","volume":"75","author":"Z Darieva","year":"2004","unstructured":"Darieva Z, Lasunskaia EB, Campos MN, Kipnis TL, Da Silva WD. Activation of phosphatidylinositol 3-kinase and c-Jun-N-terminal kinase cascades enhances NF-kappaB-dependent gene transcription in BCG-stimulated macrophages through promotion of p65\/p300 binding. J Leukoc Biol. 2004;75(4):689\u201397. https:\/\/doi.org\/10.1189\/jlb.0603280.","journal-title":"J Leukoc Biol"},{"key":"506_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00796","volume":"8","author":"A Bisiaux","year":"2017","unstructured":"Bisiaux A, Boussier J, Duffy D, Quintana-Murci L, Fontes M, Albert ML. Deconvolution of the response to Bacillus Calmette-Gu\u00e9rin reveals NF-\u03baB-induced cytokines as autocrine mediators of innate immunity. Front Immunol. 2017;8:796. https:\/\/doi.org\/10.3389\/fimmu.2017.00796.","journal-title":"Front Immunol"},{"issue":"7","key":"506_CR31","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s11655-010-0787-y","volume":"17","author":"JA Wei","year":"2011","unstructured":"Wei JA, Zeng X, Han L, Huang Y. The regulatory effects of polyporus polysaccharide on the nuclear factor kappa B signal pathway of bladder cancer cells stimulated by Bacillus Calmette-Guerin. Chin J Integr Med. 2011;17(7):531\u20136. https:\/\/doi.org\/10.1007\/s11655-010-0787-y.","journal-title":"Chin J Integr Med"},{"issue":"11","key":"506_CR32","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1007\/s11255-022-03336-9","volume":"54","author":"LO Reis","year":"2022","unstructured":"Reis LO, Salustiano ACC, Capibaribe DM, Kiehl IGA, Denardi F. Castration immunoregulates toll-like receptor-4 in male bladder cancer. Int Urol Nephrol. 2022;54(11):2845\u201353. https:\/\/doi.org\/10.1007\/s11255-022-03336-9.","journal-title":"Int Urol Nephrol"},{"issue":"1","key":"506_CR33","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41392-022-01046-3","volume":"7","author":"W Gao","year":"2022","unstructured":"Gao W, Wang X, Zhou Y, Wang X, Yu Y. Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy. Signal Transduct Target Ther. 2022;7(1):196. https:\/\/doi.org\/10.1038\/s41392-022-01046-3.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"506_CR34","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s12672-025-02509-z","volume":"16","author":"Y Li","year":"2025","unstructured":"Li Y, Tang T, Sun Y, Chen G, Yuan X, Cai D. The role of TLR-4 in chemoresistance of cancer. Discov Oncol. 2025;16(1):865. https:\/\/doi.org\/10.1007\/s12672-025-02509-z.","journal-title":"Discov Oncol"},{"key":"506_CR35","doi-asserted-by":"publisher","unstructured":"Hu H, Xia Q, Hu J, Wang S. Oncolytic Viruses for the Treatment of Bladder Cancer: Advances, Challenges, and Prospects. J Clin Med. 2022;11(23). https:\/\/doi.org\/10.3390\/jcm11236997.","DOI":"10.3390\/jcm11236997"},{"issue":"3","key":"506_CR36","doi-asserted-by":"publisher","first-page":"e93103","DOI":"10.1371\/journal.pone.0093103","volume":"9","author":"Q Zhao","year":"2014","unstructured":"Zhao Q, Zhang W, Ning Z, Zhuang X, Lu H, Liang J, et al. A Novel Oncolytic Herpes Simplex Virus Type 2 Has Potent Anti-Tumor Activity. PLoS ONE. 2014;9(3):e93103. https:\/\/doi.org\/10.1371\/journal.pone.0093103.","journal-title":"PLoS ONE"},{"issue":"4","key":"506_CR37","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/sj.gt.3301885","volume":"10","author":"BL Liu","year":"2003","unstructured":"Liu BL, Robinson M, Han ZQ, Branston RH, English C, Reay P, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003;10(4):292\u2013303. https:\/\/doi.org\/10.1038\/sj.gt.3301885.","journal-title":"Gene Ther"},{"key":"506_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106581","volume":"187","author":"Y Cao","year":"2023","unstructured":"Cao Y, Xiong F, Kan X, Guo X, Ouyang T, Wang R, et al. Transarterial viroembolization improves the therapeutic efficacy of immune-excluded liver cancer: three birds with one stone. Pharmacol Res. 2023;187:106581. https:\/\/doi.org\/10.1016\/j.phrs.2022.106581.","journal-title":"Pharmacol Res"},{"issue":"1","key":"506_CR39","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1038\/s41597-025-06133-y","volume":"12","author":"J Xu","year":"2025","unstructured":"Xu J, Ye G, An Y, Sun J, Liu C, Wang S, et al. A Multi-Omics Dataset of Prostate Cancer Response to Oncolytic Virus OH2 Treatment. Sci Data. 2025;12(1):1836. https:\/\/doi.org\/10.1038\/s41597-025-06133-y.","journal-title":"Sci Data"},{"issue":"6","key":"506_CR40","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1007\/s00262-021-03084-2","volume":"71","author":"D Ravirala","year":"2022","unstructured":"Ravirala D, Pei G, Zhao Z, Zhang X. Comprehensive characterization of tumor immune landscape following oncolytic virotherapy by single-cell RNA sequencing. Cancer Immunol Immunother. 2022;71(6):1479\u201395. https:\/\/doi.org\/10.1007\/s00262-021-03084-2.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"506_CR41","doi-asserted-by":"publisher","first-page":"e13740","DOI":"10.1111\/cpr.13740","volume":"58","author":"MJ Zhang","year":"2025","unstructured":"Zhang MJ, Lin WP, Wang Q, Wang S, Song A, Wang YY, et al. Oncolytic herpes simplex virus propagates tertiary lymphoid structure formation via CXCL10\/CXCR3 to boost antitumor immunity. Cell Prolif. 2025;58(1):e13740. https:\/\/doi.org\/10.1111\/cpr.13740.","journal-title":"Cell Prolif"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00506-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-026-00506-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00506-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T16:06:56Z","timestamp":1785514016000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43556-026-00506-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["506"],"URL":"https:\/\/doi.org\/10.1186\/s43556-026-00506-4","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"assertion":[{"value":"25 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The use of animals was approved by the Institutional Animal Care and Ethics Committee of Tongji Hospital (Approval number: TJH-202211020).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There is no competing interest.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"119"}}